{
    "name": "betibeglogene autotemcel",
    "comment": "Rx",
    "other_names": [
        "Zynteglo"
    ],
    "classes": [
        "Gene Therapies",
        "Hematologics"
    ],
    "source": "https://reference.medscape.com/drug/zynteglo-betibeglogene-autotemcel-4000275",
    "pregnancy": {
        "common": [
            "Confirm negative serum pregnancy test before start of mobilization and reconfirm before conditioning procedures and before betibeglogene autotemcel administration",
            "Data are not available regarding administration in pregnant females; consider risks to pregnancy and fertility associated with myeloablative conditioning agents ",
            "No reproductive and developmental toxicity studies in animals have been conducted"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Data are insufficient to provide recommendation on duration of contraception following treatment",
                    "Females of childbearing potential and males capable of fathering a child: Use effective contraception (ie, IUD or combination of hormonal and barrier contraception) from start of mobilization through at least 6 months after administration",
                    "Advise patients of risks associated with conditioning agents"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Data are unavailable regarding effects on fertility",
                    "Data are available on infertility risk of myeloablative conditioning",
                    "Advise patients of option to cryopreserve semen or ova before treatment, if appropriate"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available regarding presence in human milk, effect on breastfed infants, and effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abacavir",
            "description": {
                "common": "abacavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bictegravir",
            "description": {
                "common": "bictegravir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabotegravir",
            "description": {
                "common": "cabotegravir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dapivirine intravaginal",
            "description": {
                "common": "dapivirine intravaginal, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferasirox",
            "description": {
                "common": "betibeglogene autotemcel increases effects of deferasirox by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Discontinue iron chelators at least 7 days before starting conditioning.  Some iron chelators are myelosuppressive. After infusion, avoid use of these iron chelators for 6 months. If iron chelation is needed, consider administration of nonmyelosuppressive iron chelators. Phlebotomy can be used in lieu of iron chelation, when appropriate."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "betibeglogene autotemcel increases effects of deferiprone by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Discontinue iron chelators at least 7 days before starting conditioning.  Some iron chelators are myelosuppressive. After infusion, avoid use of these iron chelators for 6 months. If iron chelation is needed, consider administration of nonmyelosuppressive iron chelators. Phlebotomy can be used in lieu of iron chelation, when appropriate."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferoxamine",
            "description": {
                "common": "betibeglogene autotemcel increases effects of deferoxamine by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Discontinue iron chelators at least 7 days before starting conditioning.  Some iron chelators are myelosuppressive. After infusion, avoid use of these iron chelators for 6 months. If iron chelation is needed, consider administration of nonmyelosuppressive iron chelators. Phlebotomy can be used in lieu of iron chelation, when appropriate."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "delavirdine",
            "description": {
                "common": "delavirdine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "didanosine",
            "description": {
                "common": "didanosine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dolutegravir",
            "description": {
                "common": "dolutegravir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "doravirine",
            "description": {
                "common": "doravirine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elvitegravir",
            "description": {
                "common": "elvitegravir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "emtricitabine",
            "description": {
                "common": "emtricitabine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enfuvirtide",
            "description": {
                "common": "enfuvirtide, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fostemsavir",
            "description": {
                "common": "fostemsavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "hydroxyurea, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take hydroxyurea for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibalizumab",
            "description": {
                "common": "ibalizumab, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lamivudine",
            "description": {
                "common": "lamivudine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "raltegravir",
            "description": {
                "common": "raltegravir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "rilpivirine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "stavudine",
            "description": {
                "common": "stavudine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tenofovir DF",
            "description": {
                "common": "tenofovir DF, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zidovudine",
            "description": {
                "common": "zidovudine, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "betibeglogene autotemcel, adenovirus types 4 and 7 live, oral. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "BCG vaccine live",
            "description": {
                "common": "betibeglogene autotemcel, BCG vaccine live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "betibeglogene autotemcel, cholera vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "betibeglogene autotemcel, dengue vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "Ebola Zaire vaccine",
            "description": {
                "common": "betibeglogene autotemcel, Ebola Zaire vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine quadrivalent, intranasal",
            "description": {
                "common": "betibeglogene autotemcel, influenza virus vaccine quadrivalent, intranasal. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles (rubeola) vaccine",
            "description": {
                "common": "betibeglogene autotemcel, measles (rubeola) vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles mumps and rubella vaccine, live",
            "description": {
                "common": "betibeglogene autotemcel, measles mumps and rubella vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "measles, mumps, rubella and varicella vaccine, live",
            "description": {
                "common": "betibeglogene autotemcel, measles, mumps, rubella and varicella vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "poliovirus vaccine live oral trivalent",
            "description": {
                "common": "betibeglogene autotemcel, poliovirus vaccine live oral trivalent. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rotavirus oral vaccine, live",
            "description": {
                "common": "betibeglogene autotemcel, rotavirus oral vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rubella vaccine",
            "description": {
                "common": "betibeglogene autotemcel, rubella vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) and monkeypox vaccine, live, nonreplicating",
            "description": {
                "common": "betibeglogene autotemcel, smallpox (vaccinia) vaccine, attenuated. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, attenuated",
            "description": {
                "common": "betibeglogene autotemcel, smallpox (vaccinia) vaccine, attenuated. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "smallpox (vaccinia) vaccine, live",
            "description": {
                "common": "betibeglogene autotemcel, smallpox (vaccinia) vaccine, live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid polysaccharide vaccine",
            "description": {
                "common": "betibeglogene autotemcel, typhoid polysaccharide vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "typhoid vaccine live",
            "description": {
                "common": "betibeglogene autotemcel, typhoid vaccine live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "varicella virus vaccine live",
            "description": {
                "common": "betibeglogene autotemcel, varicella virus vaccine live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "yellow fever vaccine",
            "description": {
                "common": "betibeglogene autotemcel, yellow fever vaccine. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zoster vaccine live",
            "description": {
                "common": "betibeglogene autotemcel, zoster vaccine live. Other (see comment). Use Caution/Monitor. \nComment: Follow institutional guidelines for vaccine administration. Safety of live vaccines during or following treatment not studied. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Mucositis",
            "percent": "95"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "51"
        },
        {
            "name": "Vomiting",
            "percent": "49"
        },
        {
            "name": "Pyrexia",
            "percent": "49"
        },
        {
            "name": "Alopecia",
            "percent": "44"
        },
        {
            "name": "Epistaxis",
            "percent": "42"
        },
        {
            "name": "Abdominal pain",
            "percent": "39"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "37"
        },
        {
            "name": "Cough",
            "percent": "34"
        },
        {
            "name": "Headache",
            "percent": "29"
        },
        {
            "name": "Diarrhea",
            "percent": "27"
        },
        {
            "name": "Rash",
            "percent": "27"
        },
        {
            "name": "Nausea",
            "percent": "24"
        },
        {
            "name": "Constipation",
            "percent": "24"
        },
        {
            "name": "Decreased appetite",
            "percent": "24"
        },
        {
            "name": "Pigment disorder",
            "percent": "24"
        },
        {
            "name": "Pruritus",
            "percent": "22"
        },
        {
            "name": "Viral infection",
            "percent": "17"
        },
        {
            "name": "Procedural pain",
            "percent": "15"
        },
        {
            "name": "Transfusion reaction",
            "percent": "15"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "15"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "12"
        },
        {
            "name": "Fatigue",
            "percent": "12"
        },
        {
            "name": "Dyspnea",
            "percent": "12"
        },
        {
            "name": "Hypoxia",
            "percent": "12"
        },
        {
            "name": "Rhinitis",
            "percent": "12"
        },
        {
            "name": "Neutropenia",
            "percent": "100"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "100"
        },
        {
            "name": "Leukopenia",
            "percent": "100"
        },
        {
            "name": "Anemia",
            "percent": "95"
        },
        {
            "name": "Mucositis",
            "percent": "63"
        },
        {
            "name": "Lymphopenia",
            "percent": "61"
        },
        {
            "name": "Febrile neutropenia",
            "percent": "51"
        },
        {
            "name": "ALT increased",
            "percent": "24"
        },
        {
            "name": "Hypophosphatemia",
            "percent": "20"
        },
        {
            "name": "Epistaxis",
            "percent": "20"
        },
        {
            "name": "Decreased appetite",
            "percent": "15"
        },
        {
            "name": "Hyperglycemia",
            "percent": "14"
        },
        {
            "name": "Hypokalemia",
            "percent": "12"
        },
        {
            "name": "Pyrexia",
            "percent": "12"
        },
        {
            "name": "Dyspepsia",
            "percent": "10"
        },
        {
            "name": "Gingival bleeding",
            "percent": "10"
        },
        {
            "name": "Hypertension",
            "percent": "10"
        },
        {
            "name": "Sepsis",
            "percent": "10"
        },
        {
            "name": "Veno",
            "percent": "10"
        },
        {
            "name": "occlusive liver disease",
            "percent": "10"
        },
        {
            "name": "Hyperbilirubinemia",
            "percent": "10"
        },
        {
            "name": "Hyponatremia",
            "percent": "10"
        },
        {
            "name": "Sepsis",
            "percent": "7"
        },
        {
            "name": "Hypoxia",
            "percent": "7"
        },
        {
            "name": "Veno",
            "percent": "5"
        },
        {
            "name": "occlusive liver disease",
            "percent": "2"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        },
        {
            "name": "Gingival bleeding",
            "percent": "2"
        },
        {
            "name": "Viral infection",
            "percent": "2"
        },
        {
            "name": "Nausea",
            "percent": "7"
        },
        {
            "name": "Abdominal pain",
            "percent": "7"
        },
        {
            "name": "Infections and infestations",
            "percent": "2"
        },
        {
            "name": "Pneumonia",
            "percent": "2"
        },
        {
            "name": "Infusion",
            "percent": null
        },
        {
            "name": "related reactions",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "tachycardia",
            "percent": null
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Congestive heart failure",
            "percent": null
        }
    ]
}